A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

NCT06561425 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell

Interventions

GENETIC: GLPG5101

Sponsor

Lakefront Biotherapeutics NV